



Cutting-edge medicine needs
**CUTTING-EDGE
EQUIPMENT**

Scrubs in the City supports the most critical needs with tangible impact at SickKids. This year's fundraising will go towards upgrading essential equipment in the neurophysiology and neurodiagnostic labs to treat conditions like tumours, epilepsy and stroke. State-of-the-art technology translates into shorter waiting times, faster diagnoses, newer treatments, more precise surgeries, and brighter futures.

SickKids **VS**[®]

NEW TECH IS CHANGING

how we diagnose and treat

The SickKids neurophysiology and neurodiagnostic teams are constantly working to pioneer new treatments for kids with brain and spinal tumours, epilepsy, stroke, trauma, and more, which demands keeping pace with technological innovation. Continuous investment in lab equipment such as

EEG machines, MRIs, and CT scanners is critical to understanding rare conditions like Shaan's, staying current with clinical advances, and delivering the highest quality healthcare. Neurotechnological improvements lead to greater insight into brain or nervous system activity and have the potential to unlock novel treatments for kids like Shaan.

DIAGNOSING SHAAN

At only a few days old, Shaan was admitted to SickKids after having a seizure. He spent the next few weeks in the neonatal intensive care unit, where he experienced up to 30 seizures a day. Shaan needed round-the-clock care, numerous procedures, and many medications to control the seizures. He was eventually transferred to the SickKids neurology and epilepsy ward, where experts used state-of-the-art equipment and sequencing technology to determine why Shaan was seizing and how to stop it. The team discovered an ultra-rare gene variation that led to the diagnosis of an intractable condition known as KCNT1-related epilepsy. While there is currently no cure for his epilepsy, doctors offered Shaan an evolving therapy, which reduces the frequency of his seizures and improves his and his family's quality of life. As a complex care patient, Shaan will continue to be monitored at SickKids and benefit from any future discoveries.

